脑部MR成像中眼部结构的钆延迟渗漏:患病率及相关因素
该回顾性研究分析了439例在7天内接受钆对比剂注射后行脑部MR成像的患者,发现26例(6%)出现眼部结构钆渗漏(GLOS)。GLOS多见于注射后25-72小时,并与较低的估算肾小球滤过率和较短的注射后时间间隔独立相关。作者指出GLOS可能是一种生理性钆排泄途径,但未正式评估眼部疾病。
要点
- 脑部MR FLAIR序列上发现眼球腔内高信号时,应结合7天内钆对比剂注射史考虑GLOS。
- GLOS患病率约6%,最常见于注射后25-72小时(54%的GLOS病例)。
- GLOS患者年龄更大、血清肌酐更高、eGFR更低,且注射后时间间隔更短。
核心结论
- GLOS仅见于小部分在脑部MR成像前7天内接受钆对比剂的患者,可见于脑部MR正常者及各种中枢神经系统病变患者,与较低eGFR和较短注射后时间间隔相关;作者认为GLOS可能是一种生理性钆对比剂排泄途径,但未正式评估眼部疾病,认识GLOS仍有助于恰当的影像学判读。
研究设计与样本
- 回顾性分析纳入439例在先前MR检查接受钆对比剂注射后7天内行脑部MR成像的患者,收集临床、影像和实验室数据,进行描述性和逻辑回归分析。
关键影像表现/征象
- GLOS表现为FLAIR序列上眼球腔内高信号。
- GLOS组中位年龄72岁 vs 非GLOS组55岁(P = .001)。
- GLOS组中位血清肌酐73 µmol/L vs 非GLOS组64 µmol/L(P = .005)。
诊断标准与关键数值
- GLOS患病率:26/439例(6%)。
- GLOS出现时间分布:注射后24小时内3例(12%)、25-72小时14例(54%)、73-120小时8例(31%)、>120小时1例(4%)。
- GLOS组中位eGFR 84 mL/min/1.73 m2 vs 非GLOS组101 mL/min/1.73 m2(P < .001)。
- GLOS组注射至指数脑部MR的中位时间间隔62小时 vs 非GLOS组91小时(P = .003)。
- 多变量回归分析:eGFR(OR = 0.970;95% CI,0.049-0.992;P = .008)和注射后时间间隔(OR = 0.987;95% CI,0.977-0.997;P = .012)为GLOS的独立相关因素。
临床应用与阅片要点
- 作者指出认识GLOS有助于恰当的影像学判读。
- 原文未据此给出推荐。
局限性
- 纳入人群未正式评估眼部疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Gadolinium leakage in ocular structures (GLOS) is characterized by hyperintense signal in the chambers of the eye on FLAIR and has been reported in association with blood-ocular barrier breakdown in patients with ischemic strokes. The underlying mechanism of GLOS remains poorly understood; however, some studies suggest it may be part of a physiologic excretion pathway of gadolinium. This study aimed to determine the prevalence of GLOS in an unselected patient population.
MATERIALS AND METHODS: A retrospective analysis was conducted on 439 patients who underwent brain MR imaging within 7 days of receiving a gadolinium-based contrast agent injection for a prior MR imaging study. Clinical, imaging, and laboratory data were collected. Descriptive and logistic regression analyses were performed.
RESULTS: GLOS was observed in 26 of 439 patients (6%). The occurrence of GLOS varied with time, with 3 (12%), 14 (54%), 8 (31%), and 1 (4%) patient showing GLOS within 24, 25-72, 73-120, and >120 hours after gadolinium-based contrast agent injection, respectively. Patients with GLOS were older (median age: 72 versus 55 years, P = .001) and had higher median serum creatinine levels (73 versus 64 µmol/L, P = .005) and a lower median estimated glomerular filtration rate (84 versus 101 mL/min/1.73 m2, P < .001). A shorter median time interval between gadolinium-based contrast agent injection and the index brain MR imaging was observed in the group positive for GLOS (62 versus 91 hours, P = .003). Multivariable regression analysis identified the estimated glomerular filtration rate (OR = 0.970; 95% CI, 0.049-0.992; P = .008) and time interval since gadolinium-based contrast agent injection (OR = 0.987; 95% CI, 0.977-0.997; P = .012) as independent factors associated with GLOS.
CONCLUSIONS: GLOS was observed in only a small percentage of patients receiving gadolinium-based contrast agent within 7 days before brain MR imaging. This phenomenon was noted in patients with normal findings on brain MR imaging and those with various CNS pathologies, and it was associated with lower estimated glomerular filtration rates and shorter time intervals after gadolinium-based contrast agent injection. While GLOS may be a physiologic gadolinium-based contrast agent excretion pathway, the presence of ocular disease was not formally evaluated in the included population. Awareness of GLOS is nonetheless useful for appropriate radiologic interpretation.
引用
- Olatunji R, Lim TR, Jones B, et al. Delayed Gadolinium Leakage in Ocular Structures on Brain MR Imaging: Prevalence and Associated Factors. AJNR Am J Neuroradiol. 2023. PMID: 38123939. doi:10.3174/ajnr.A8073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。